成人自身免疫性肝炎二线药物治疗选择的Meta分析

钱乐; 应力

doi:10.3969/j.issn.1001-5256.2020.09.021

成人自身免疫性肝炎二线药物治疗选择的Meta分析

DOI: 10.3969/j.issn.1001-5256.2020.09.021

钱乐,
应力

1. 辽健集团本钢总医院内窥镜科
2. 大连医科大学附属第二医院消化内科

基金项目:

辽宁省自然科学基金(2019-ZD-0913)；

详细信息

中图分类号: R575.1
计量
- 文章访问数: 1167
- HTML全文浏览量: 42
- PDF下载量: 129
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis

Qian Le,
Ying Li

Department of Endoscopy, General Hospital of Benxi Iron and Steel Co., Ltd., Liaoning Health Industry Group

Research funding:

摘要

摘要:
目的通过自身免疫性肝炎二线药物相关文献的系统性回顾及Meta分析探讨药物的有效性和安全性。方法计算机检索PubMed、EMBASE、Cochrane Library、Web of Science、中国知网、中国生物医学文献数据库、万方数据库及维普数据库等公开发表的关于自身免疫性肝炎二线药物治疗的研究文献,时间截至2019年12月31日。对纳入的文献采用纽卡斯尔-渥太华量表进行文献质量评价,提取相关数据,采用Meta-Analyst统计软件进行Meta分析。结果纳入22篇文献,共计636例患者。Meta分析结果显示,吗替麦考酚酯（MMF）、他克莫司（TAC）、环孢素（CsA）及布地奈德（BUD）的汇总应答率分别为56.1%、76.0%、62.7%、57.3%,汇总的不良反应发生率分别为22.5%、47.4%、48.4%、33.0%。将应用MMF的患者按照一线治疗不耐受和一线治疗无应答进行分组比较,相对危险度为1.965,95%可信区间为1.181～3.269,异质性检验I2=0.665,P=0.014。结论对于成人自身免疫性肝炎患者的二线药物治疗选择,结合应答率及不良反应发生率,MMF和...
- 肝炎,自身免疫性 /
- 药物疗法 /
- Meta分析(主题)
Abstract:
Objective To investigate the clinical effect and safety of second-line drugs in the treatment of adult patients with autoimmune hepatitis( AIH) through a Meta-analysis of related articles. Methods PubMed,EMBASE,Cochrane Library,Web of Science,CNKI,CBM,Wanfang Data,and VIP were searched for the articles on second-line drugs for AIH published up to December 31,2019. The Newcastle-Ottawa Scale( NOS) was used to assess the quality of articles,related data were extracted,and Meta-Analyst software was used to perform the Meta-analysis. Results A total of 22 articles were included,with 636 patients in total. The Meta-analysis showed that mycophenolate mofetil( MMF),tacrolimus( TAC),cyclosporine,and budesonide had a pooled response rate of 56. 1%,76. 0%,62. 7%,and 57. 3%,respectively,and their pooled incidence rates of adverse events were 22. 5%,47. 4%,48. 4%,and 33. 0%,respectively.The patients treated with MMF were divided into groups based on intolerance or no response to the first-line treatment,and a comparative analysis of these groups showed a relative risk of 1. 965( 95% confidence interval: 1. 181-3. 269,I2= 0. 665,P = 0. 014). Conclusion Selection of second-line drugs for adult AIH patients should consider response rate and incidence rate of adverse reactions. Both MMF and tacrolimus are good second-line drugs,and TAC may be a better choice for patients with no response to first-line treatment.
- hepatitis,autoimmune /
- drug therapy /
- Meta-analysis as topic

HTML全文

参考文献(29)

[1] WALDENSTROM J. Liver,blood proteins and nutritive protein[J]. Dtsch Z Verdau Stoffwechselkr,1953,9:113-119.

[2] JOHNSON PJ,MCFARLANE IG. Meeting report:International Autoimmune Hepatitis Group[J]. Hepatology,1993,18(4):998-1005.

[3] ROBERTS SK,KEMP W. Salvage therapies for autoimmune hepatitis:A critical review[J]. Semin Liver Dis,2017,37(4):343-362.

[4] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.

[5] SHI JJ,TAN YW. Meta-analysis of the efficacy and safety of budesonide and prednisone in combination with azathioprine respectively in the treatment of autoimmune hepatitis[J/CD].Chin J Liver Dis(Electronic Version),2019,11(3):36-41.(in Chinese)史浚颉，谭友文．布地奈德与泼尼松分别联合硫唑嘌呤治疗自身免疫性肝炎疗效与安全性的Meta分析[J/CD]．中国肝脏病杂志(电子版)，2019,11(3):36-41.

[6] ZIZZO AN,VALENTINO PL,SHAH PS,et al. Second-line agents in pediatric patients with autoimmune hepatitis:A systematic review and meta-analysis[J]. J Pediatr Gastroenterol Nutr,2017,65(1):6-15.

[7] DANIELSSON A,PRYTZ H. Oral budesonide for treatment of autoimmune chronic active hepatitis[J]. Aliment Pharmacol Ther,1994,8(6):585-590.

[8] FERNANDES NF,REDEKER AG,VIERLING JM,et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis[J]. Am J Gastroenterol,1999,94(1):241-248.

[9] CZAJA AJ,LINDOR KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis[J]. Gastroenterology,2000,119(5):1312-1316.

[10] RICHARDSON PD,JAMES PD,RYDER SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine[J]. J Hepatol,2000,33(3):371-375.

[11] MALEKZADEH R,NASSERI-MOGHADDAM S,KAVIANI MJ,et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis[J]. Dig Dis Sci,2001,46(6):1321-1327.

[12] AQEL BA,MACHICAO V,ROSSER B,et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis[J]. J Clin Gastroenterol,2004,38(9):805-809.

[13] DEVLIN SM,SWAIN MG,URBANSKI SJ,et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy[J]. Can J Gastroenterol,2004,18(5):321-326.

[14] CZAJA AJ,CARPENTER HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil:Comparison with conventional treatment for refractory disease[J]. J Clin Gastroenterol,2005,39(9):819-825.

[15] CHATUR N,RAMJI A,BAIN VG,et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis:The Canadian association for the study of liver(CASL)experience with mycophenolate mofetil and tacrolimus[J]. Liver Int,2005,25(4):723-727.

[16] CSEPREGI A,RCKEN C,TREIBER G,et al. Budesonide induces complete remission in autoimmune hepatitis[J]. World J Gastroenterol,2006,12(9):1362-1366.

[17] INDUCTIVO-YU I,ADAMS A,GISH RG,et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy[J]. Clin Gastroenterol Hepatol,2007,5(7):799-802.

[18] HLIVKO JT,SHIFFMAN ML,STRAVITZ RT,et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2008,6(9):1036-1040.

[19] HENNES EM,OO YH,SCHRAMM C,et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?[J].Am J Gastroenterol,2008,103(12):3063-3070.

[20] ZANDIEH I,KRYGIER D,WONG V,et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada[J].Can J Gastroenterol,2008,22(4):388-392.

[21] SHARZEHI K,HUANG MA,SCHREIBMAN IR,et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy[J].Can J Gastroenterol,2010,24(10):588-592.

[22] EFE C,HAGSTRM H,YTTING H,et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2017,15(12):1950-1956.

[23] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267.

[24] ROBERTS SK,LIM R,STRASSER S,et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy[J]. Clin Gastroenterol Hepatol,2018,16(2):268-277.

[25] HUANG ZJ,XU ZJ,ZENG CP. Clinical efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis[J].Hainan Med J,2013,24(21):3143-3145.(in Chinese)黄志杰，许正锯，曾翠萍．他克莫司治疗类固醇抗性自身免疫性肝炎的临床疗效分析[J]．海南医学，2013,24(21):3143-3145.

[26] BAVEN-PRONK AM,COENRAAD MJ,van BUUREN HR,et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes[J]. Aliment Pharmacol Ther,2011,34(3):335-343.

[27] GIANNAKOPOULOS G,VERBAAN H,FRIIS-LIBY IL,et al.Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine[J]. Dig Liver Dis,2019,51(2):253-257.

[28] PAPE S,NEVENS F,VERSLYPE C,et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors:A realworld-experience[J]. Eur J Gastroenterol Hepatol,2020,32(6):727-732.

[29] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.

施引文献

资源附件(0)

访问统计